News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Pulmatrix (NASDAQ:PULM) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Pulmatrix (NASDAQ:PULM) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Pulmatrix (NASDAQ:PULM) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Pulmatrix (NASDAQ:PULM) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

Form 8-K Pulmatrix, Inc. For: Dec 17

Form 10-Q Pulmatrix, Inc. For: Sep 30

Form 8-K Pulmatrix, Inc. For: Oct 16

Top News Decliners

4/16 Pulmatrix Announces $8.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules -28.6%

3/26 Form 10-K Pulmatrix, Inc. For: Dec 31 -15.7%

1/30 Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA -12.9%

4/16 Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19 -10.2%

4/24 Form SC 13G Pulmatrix, Inc. Filed by: ARMISTICE CAPITAL, LLC -7.7%

8/19 Pulmatrix Receives US Patent Covering iSPERSE™ Formulations for Pulmazole Program -6.7%

3/9 Pulmatrix Inc (NASDAQ: PULM) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -6.5%

11/1 Q3/2019 9/30/2019 EPS -0.180 ZacksConsensus N/A ActVsEst N/A - N/A -6.5%

2/11 Form SC 13G/A Pulmatrix, Inc. Filed by: INTRACOASTAL CAPITAL, LLC -6.0%

11/14 Pulmatrix Inc (NASDAQ: PULM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.00 price target on the stock. -5.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}